Locomotive syndrome in rheumatoid arthritis patients during the COVID-19 pandemic

Yasumori Sobue1, Mochihito Suzuki2,3, Yoshifumi Ohashi2,4, Hiroshi Koshima3, Nobuyuki Okui4, Koji Funahashi5, Hisato Ishikawa1, Hidenori Inoue1, Masayo Kojima6, Shuji Asai2, Kenya Terabe2, Kyosuke Hattori2, Kenji Kishimoto2, Nobunori Takahashi2, Shiro Imagama2 and Toshihisa Kojima2

1Department of Orthopedic Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan
2Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
3Department of Orthopedic Surgery, Japan Community Health care Organization Kani Tono Hospital, Kani, Japan
4Department of Orthopedic Surgery, Yokkaichi Municipal Hospital, Yokkaichi, Japan
5Department of Orthopedic Surgery, Kariya Toyota General Hospital, Kariya, Japan
6Department of Frailty Research, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan

ABSTRACT

This study aimed to longitudinally evaluate the development of locomotive syndrome (LS) in rheumatoid arthritis (RA) patients during the COVID-19 pandemic using the 25-question Geriatric Locomotive Function Scale (GLFS-25). Subjects were 286 RA patients (female, 70.6%; mean age, 64.2 years) who had GLFS-25 and Clinical Disease Activity Index (CDAI) data available for a 1-year period during the COVID-19 pandemic and who did not have LS at baseline. Associations between subject characteristics and development of LS were determined using logistic regression analysis. Among the 286 patients, 38 (13.3%, LS group) developed LS at 1 year after baseline. In the LS group, scores of the GLFS-25 categories “GLFS-5” and “Social activities” were significantly increased at 1 year relative to baseline. GLFS-5 is a quick 5-item version of the GLFS-25, including questions regarding the difficulty of going up and down stairs, walking briskly, distance able to walk without rest, difficulty carrying objects weighing 2 kg, and ability to carry out load-bearing tasks and housework. A significant correlation was also observed between changes in “Social activities” and that of “GLFS-5.” Multivariable logistic regression analysis revealed that the development of LS was significantly associated with BMI (OR: 1.11 [95% confidence interval (CI): 1.00–1.22]) and CDAI (OR: 1.08 [95%CI: 1.00–1.16]) at baseline. Adequate exercise and tight control of RA disease activity are important for preventing the development of LS in view of restrictions on going out imposed during the COVID-19 pandemic. GLFS-5 is useful for evaluating the physical function of RA patients.

Keywords: COVID-19, locomotive syndrome, rheumatoid arthritis, 25-question Geriatric Locomotive Function Scale (GLFS-25), Clinical Disease Activity Index (CDAI)
INTRODUCTION

Coronavirus disease 2019 (COVID-19) has spread globally with devastating impact.1-3 COVID-19 can cause shortness of breath, fever, and fatal pneumonia in the most progressive and worst cases. Rheumatoid arthritis (RA) patients, who are often on immunosuppressants, need to pay close attention to COVID-19.4,5 The Japanese government has taken various measures to prevent the spread of COVID-19, including declaring a state of emergency and a requirement to refrain from going out.6 Consequently, physical activity in the general population has decreased since the appearance of the disease.7 An extended period of inactivity can lead to the deterioration of physical function and development of locomotive syndrome (LS).

LS is a concept proposed by the Japanese Orthopedic Association in 2007 as a national health policy target and refers to a condition of reduced mobility due to disorders of the musculoskeletal system (bones, joints, and muscles). It is a high-risk condition that requires caregiving and can lead to a bedridden state.8,9 Since LS impacts frailty, quality of life and healthy life expectancy,10-12 its prevention is highly important. RA, which can lead to the degeneration of cartilage, destruction of bones and joint structure, and rapid joint damage, especially in the lower limbs, can reduce mobility from a young age. Moreover, since aging of the RA population is progressing, RA is one of the causative diseases of LS.14-16 In fact, the proportion of RA patients with LS is estimated to be higher than that of the general Japanese population at each age.17,18

It is thus clear that RA patients are susceptible and vulnerable to LS, and this might be exacerbated by refraining from going out. Therefore, it is important for rheumatologists to evaluate the physical function of RA patients from the perspective of LS. To this end, the present study aimed to examine the development of LS in RA patients during the COVID-19 pandemic.

MATERIALS AND METHODS

Subjects

A total of 581 RA patients consecutively visited Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Japan Community Health care Organization Kani Tono Hospital, and Yokkaichi Municipal Hospital between June and August 2020 (Tsurumai - Frailty and Locomotive syndrome of rheumatoid Arthritis for Globalization, T-FLAG Study, which began in 2020 for the purpose of analyzing frailty and locomotive syndrome of RA patients in clinical practice; enrollment started on June 1, 2020). Among these patients, data on clinical characteristics, including scores for the 25-question Geriatric Locomotive Function Scale (GLFS-25)20 and Clinical Disease Activity Index (CDAI)21 were available for 538, all of whom fulfilled the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.22 Non-LS and LS are defined as GLFS-25 <16 points and ≥16 points, respectively.10 Among the 538 patients, 325 belonged to the non-LS group, and GLFS-25 and CDAI data were available
RA locomotive syndrome and COVID-19

for 286 during the period of June-August 2021. Reasons for patient drop-out from the follow-up study were unclear, but there were no significant differences in patient baseline characteristics except for C-reactive protein (CRP) and the proportion of methotrexate (MTX) use between the 286 patients in this study and the remaining 39 patients (data not shown). Documented subject characteristics included age, duration of disease, sex, body mass index (BMI), marital status, and school education (number of years in school), Steinbrocker classification stage (evaluated at the most progressed joint),23 drug therapy (glucocorticoid (GC), MTX, other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including salazosulfapyridine, tacrolimus, bucillamine, and iguratimod, and biological DMARDs (bDMARDs)/targeted synthetic DMARDs (tsDMARDs)), rheumatoid factor (RF), CRP, swollen and tender 28-joint count (SJC and TJC), subject’s global assessment of disease activity visual analog scale (VAS), physician’s global assessment of disease activity VAS, CDAI,21 Health Assessment Questionnaire-Disability Index (HAQ-DI),24 Kihon Checklist (KCL),25,26 and GLFS-25. CDAI is the simple sum of SJC, TJC, subject’s global assessment of disease activity VAS (0–10 scale), and physician’s global assessment of disease activity VAS (0–10 scale).21 Since the analysis included RA patients being treated with interleukin-6 receptor inhibitors and Janus kinase inhibitors, we used CDAI to evaluate disease activity rather than composite measures using CRP. CDAI was categorized as follows: remission (CDAI ≤2.8); low disease activity (LDA; 2.8< CDAI ≤10); moderate disease activity (MDA; 10< CDAI ≤22); and high disease activity (HDA; CDAI >22).21

This retrospective study was approved by the Ethics Committees of Nagoya University School of Medicine (2017-0271), Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital (2020-451), Japan Community Health care Organization Kani Tono Hospital (20110901), and Yokkaichi Municipal Hospital (2017-29). As this study involved retrospective research, rather than obtaining consent from each patient, we disclosed information pertaining to the study at the cooperating facilities according to the procedure stipulated by the Ethics Committees.

25-question Geriatric Locomotive Function Scale (GLFS-25)

GLFS-25 is a screening tool developed for the early detection of LS. The scale consists of 25 questions in total, including four questions regarding “Body pain” during the last month (Nos. 1, 2, 3, and 4) and 21 questions regarding “Movement-related difficulty” (Nos. 5, 6, and 7), “Usual care” (Nos. 8, 9, 10, 11, and 14), “GLFS-5” (Nos. 12, 13, 15, 17, and 20), “Social activities” (Nos. 18, 21, 22, and 23), and “Cognitive” (Nos. 24 and 25) during the last month.20 GLFS-5 was set as the key domain and consists of questions regarding the difficulty of going up and down stairs, walking briskly, distance able to walk without rest, difficulty carrying objects weighing 2 kg, and ability to carry out load-bearing tasks and housework.20 The scale is based on a 5-point system, with 0 points assigned for no impairment to 4 points for severe impairment. Total scores range from 0 (no symptom) to 100 (most severe) points. LS grade is defined as follows: GLFS-25 <7 points corresponds to Stage 0; 7–15 points corresponds to Stage 1; 16–23 points corresponds to Stage 2,10 and ≥24 points corresponds to Stage 3.27 “Stage 1” marks the beginning of the decline in mobility function, “Stage 2” reflects progression of the decline, and “Stage 3” reflects progression to the extent that it interferes with social participation. Seichi et al reported on the reliability and validity of GLFS-25 and set a cut-off of 16 points for identifying LS (ie, Stage 2).20

Statistical analysis

Continuous variables are expressed as mean and standard deviation (SD) and were analyzed using the Mann-Whitney U test. Ordinal variables and categorical variables are expressed as percentages and were analyzed using Fisher’s exact test. Differences between two surveys
were examined by Wilcoxon’s signed rank test. Multivariable logistic regression analyses were performed to confirm the independent impact of variables on the development of LS. Among the assessed variables (age, duration of disease, sex, BMI, marital status, school education, Steinbrocker stage, GC use, MTX use, other csDMARD use, bDMARD/tsDMARD use, RF positive, CDAI, KCL, and GLFS-25, all at baseline), those with a p value <0.10 in the univariable analyses were included in the multivariable model. Linear regression analyses were performed to explore factors contributing to changes in the GLFS-25 at 1 year after baseline. Receiver operating characteristic (ROC) curves were generated to assess associations between LS at 1 year after baseline and BMI, CDAI, and GLFS-25 at baseline. The best cut-off point was identified as the maximum point of the Youden index, which was calculated using the following formula: 
\[ \text{Youden index} = \text{sensitivity} + \text{specificity} - 1 \]
Finally, correlations between changes in GLFS-25 categories were analyzed using Spearman’s rank correlation coefficients.

Statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan; http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmed.html), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). P<0.05 was considered statistically significant.

### RESULTS

Of the 286 subjects (202 females, 70.6%), 38 (13.3%) had developed LS at 1 year after baseline. Demographics and clinical characteristics at baseline are summarized in Table 1. Mean age at baseline (standard deviation (SD)) was 63.6 (16.0) / 64.3 (12.7) years (LS group / non-LS group), disease duration was 8.6 (9.1) / 10.8 (9.0) years, BMI was 23.7 (3.9) / 21.8 (3.6) kg/m², CDAI was 5.7 (5.1) / 3.3 (4.9), and GLFS-25 was 9.6 (3.4) / 6.3 (4.4) points. BMI, CDAI, and GLFS-25 were significantly higher in the LS group than in the non-LS group at baseline.

Figure 1a shows changes in GLFS-25 for the LS and non-LS groups over the 1-year study period. For GLFS-25 in both the LS and non-LS groups, scores were significantly increased at 1 year relative to baseline. Figures 1b and 1c show changes of each GLFS-25 category in the non-LS and LS groups, respectively. While only the “Social activities” category showed a significant increase in the non-LS group, all categories, in particular, “Social activities”, “Body pain”, “Cognitive”, and “GLFS-5” categories, showed a significant increase in the LS group at 1 year relative to baseline. The category “Social activities” in the LS group showed the largest increase at 1 year relative to baseline.

Table 2 shows changes in the median score for each question of the GLFS-25 for the non-LS group during the 1-year study period. Median scores for question Nos. 22 and 23 (two questions from “Social activities”) were increased at 1 year relative to baseline. Table 3 shows changes in the median score for each question of the GLFS-25 for the LS group during the 1-year study period. Question Nos. 1, 2, 3, and 4 (all questions from “Body pain”); 13 and 15 (two questions from “GLFS-5”); 23 (one question from “Social activities”); and 25 (one question from “Cognitive”) already had a median above 0 points (no symptom) at baseline. Significant differences were observed between baseline and 1 year later for all questions except for question Nos. 2, 7, 8, and 9. Median scores for question Nos. 12, 13, 15, 17, and 20 (all questions from “GLFS-5”); 21, 22, and 23 (three questions from “Social activities”, which increased by over 1 point); and 24 (one question from “Cognitive”) were increased at 1 year relative to baseline.
Table 1 Demographics and clinical characteristics of subjects at baseline

| Variables                                      | Total (n=286) | LS group (n=38) | non-LS group (n=248) | p value |
|------------------------------------------------|---------------|-----------------|-----------------------|---------|
| Age (years) Mean (SD)                          | 64.2 (13.1)   | 63.6 (16.0)     | 64.3 (12.7)           | 0.995   |
| Duration of disease (years) Mean (SD)          | 10.5 (9.0)    | 8.6 (9.1)       | 10.8 (9.0)            | 0.028   |
| Sex, female (%)                                |               |                 |                       |         |
| BMI (kg/m²) Mean (SD)                          | 22.0 (3.7)    | 23.7 (3.9)      | 21.8 (3.3)            | 0.009   |
| Married (%)                                    |               |                 |                       |         |
| School education ≥13 years (%)                 |               |                 |                       |         |
| Steinbrocker stage (3/4) (%)                   |               |                 |                       |         |
| Glucocorticoid use (%)                         |               |                 |                       |         |
| Methotrexate use (%)                           |               |                 |                       |         |
| Other csDMARD use (%)                          |               |                 |                       |         |
| bDMARD/tsDMARD use (%)                         |               |                 |                       |         |
| Rheumatoid factor positive (%)                 |               |                 |                       |         |
| CRP (mg/dl) Mean (SD)                          | 0.22 (0.39)   | 0.19 (0.26)     | 0.22 (0.41)           | 0.924   |
| Swollen 28-joint count Mean (SD)               | 0.5 (1.7)     | 0.7 (1.9)       | 0.5 (1.6)             | 0.410   |
| Tender 28-joint count Mean (SD)                | 1.0 (1.9)     | 1.3 (2.2)       | 0.9 (1.9)             | 0.211   |
| Subject’s global assessment of disease activity VAS (mm) Mean (SD) | 11.6 (15.7) | 19.3 (18.6) | 10.4 (14.9) | <0.001 |
| Physician’s global assessment of disease activity VAS (mm) Mean (SD) | 9.5 (13.5) | 18.1 (16.6) | 8.2 (12.5) | <0.001 |
| CDAI Mean (SD)                                 | 3.6 (5.0)     | 5.7 (5.1)       | 3.3 (4.9)             | 0.001   |
| HAQ-DI Mean (SD)                               | 0.11 (0.21)   | 0.18 (0.24)     | 0.10 (0.21)           | 0.004   |
| KCL Mean (SD)                                  | 4.5 (3.0)     | 5.7 (3.6)       | 4.3 (2.8)             | 0.017   |
| GLFS-25 Mean (SD)                              | 6.8 (4.4)     | 9.6 (3.4)       | 6.3 (4.4)             | <0.001   |

LS: locomotive syndrome
BMI: body mass index
DMARD: disease-modifying antirheumatic drugs
csDMARD: conventional synthetic DMARD
bDMARD: biological DMARD
tsDMARD: targeted synthetic DMARD
CRP: C-reactive protein
VAS: visual analog scale
CDAI: Clinical Disease Activity Index
HAQ-DI: Health Assessment Questionnaire-Disability Index
KCL: The Kihon Checklist
SD: standard deviation
GLFS-25: 25-question Geriatric Locomotive Function Scale
Locomotive syndrome was defined as ≥16 points on the GLFS-25. Other csDMARDs include salazosulfapyridine, tacrolimus, bucillamine, and iguratimod.
P<0.05 was considered statistically significant.
Yasumori Sobue et al

Fig. 1 Mean changes in GLFS-25 over the 1-year study period
Fig. 1a: Mean changes in GLFS-25.
Fig. 1b: Mean changes in each GLFS-25 category in the non-LS group.
Fig. 1c: Mean changes in each GLFS-25 category in the LS group.

(*) P<0.05, (*** ) P<0.001 (Baseline vs 1 year).

Error bars represent standard deviations. “Body pain” includes question Nos. 1, 2, 3, and 4. “Movement-related difficulty” includes question Nos. 5, 6, and 7. “Usual care” includes question Nos. 8, 9, 10, 11, and 14. “GLFS-5” includes question Nos. 12, 13, 15, 17, and 20. “Social activities” includes question Nos. 18, 21, 22, and 23.

GLFS-25: 25-question Geriatric Locomotive Function Scale
LS: locomotive syndrome
GLFS-5: 5-question Geriatric Locomotive Function Scale

Table 2 Changes in median points of GLFS-25 in non-LS group

| GLFS-25 items                                      | Baseline (2020) | 1 year (2021) | p value |
|---------------------------------------------------|-----------------|---------------|---------|
| 1. Neck or upper limb pain                        | 1.0 [0.0, 1.0]  | 1.0 [0.0, 1.0]| 0.048   |
| 2. Back, lower back, or buttocks pain             | 0.0 [0.0, 1.0]  | 0.0 [0.0, 1.0]| 0.931   |
| 3. Lower limb pain                                | 0.0 [0.0, 1.0]  | 0.0 [0.0, 1.0]| 0.229   |
| 4. Painful to move body in daily life             | 0.0 [0.0, 1.0]  | 0.0 [0.0, 0.0]| 0.614   |
| 5. Difficult to get up from a bed or lie down     | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.655   |
| 6. Difficult to stand up from a chair             | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.063   |
| 7. Difficult to walk inside the house             | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 1.000   |
| 8. Difficult to put on and take off shirt         | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.178   |
| 9. Difficult to put on and take off trousers and pants | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.031   |
| 10. Difficult to use the toilet                   | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.773   |
| 11. Difficult to wash body in bath                | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.393   |
| 12. Difficult to go up and down stairs            | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.409   |
| 13. Difficult to walk briskly                     | 0.0 [0.0, 1.0]  | 0.0 [0.0, 1.0]| 0.644   |
| 14. Difficult to keep oneself neat                | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.080   |
| 15. Difficult to keep walking without rest        | 0.0 [0.0, 1.0]  | 0.0 [0.0, 1.0]| 0.963   |
| 16. Difficult to go out to visit neighbors        | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.530   |
| 17. Difficult to carry objects weighing 2 kg      | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.059   |
| 18. Difficult to go out using public transportation| 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0]| 0.301   |
| 19. Difficult to carry out simple tasks and housework | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0] | 0.565 |
| 20. Difficult to carry out load-bearing tasks and housework | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0] | 0.046 |
| 21. Difficult to perform sports activities        | 0.0 [0.0, 1.0]  | 0.0 [0.0, 1.0]| 0.450   |
RA locomotive syndrome and COVID-19

Table 3 Changes in median points of GLFS-25 in LS group

| GLFS-25 items                             | Baseline (2020) | 1 year (2021) | p value |
|-------------------------------------------|-----------------|---------------|---------|
| 1. Neck or upper limb pain                | 1.0 [0.3, 1.0]  | 1.0 [1.0, 2.0] | <0.001  |
| 2. Back, lower back, or buttocks pain     | 1.0 [0.0, 1.0]  | 1.0 [0.0, 1.0] | 0.059   |
| 3. Lower limb pain                        | 1.0 [0.0, 1.0]  | 1.0 [1.0, 2.0] | 0.008   |
| 4. Painful to move body in daily life      | 1.0 [0.0, 1.0]  | 1.0 [1.0, 1.8] | 0.004   |
| 5. Difficult to get up from a bed or lie down | 0.0 [0.0, 0.0]  | 0.0 [0.0, 1.0] | 0.021   |
| 6. Difficult to stand up from a chair      | 0.0 [0.0, 0.0]  | 0.0 [0.0, 1.0] | 0.012   |
| 7. Difficult to walk inside the house      | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0] | 0.110   |
| 8. Difficult to put on and take off shirt  | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0] | 0.065   |
| 9. Difficult to put on and take off trousers and pants | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.8] | 0.127   |
| 10. Difficult to use the toilet            | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0] | 0.025   |
| 11. Difficult to wash body in bath         | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0] | 0.029   |
| 12. Difficult to go up and down stairs     | 0.0 [0.0, 1.0]  | 1.0 [1.0, 1.0] | <0.001  |
| 13. Difficult to walk briskly              | 0.5 [0.0, 1.0]  | 1.0 [1.0, 2.0] | <0.001  |
| 14. Difficult to keep oneself neat         | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.0] | 0.015   |
| 15. Difficult to keep walking without rest | 0.5 [0.0, 1.0]  | 1.0 [1.0, 2.0] | <0.001  |
| 16. Difficult to go out to visit neighbors | 0.0 [0.0, 0.0]  | 0.0 [0.0, 0.8] | 0.003   |
| 17. Difficult to carry objects weighing 2 kg | 0.0 [0.0, 0.0]  | 1.0 [0.0, 1.0] | 0.001   |
| 18. Difficult to go out using public transportation | 0.0 [0.0, 0.0]  | 0.0 [0.0, 1.0] | 0.002   |
| 19. Difficult to carry out simple tasks and housework | 0.0 [0.0, 0.0]  | 0.0 [0.0, 1.0] | 0.006   |
| 20. Difficult to carry out load-bearing tasks and housework | 0.0 [0.0, 1.0]  | 1.0 [0.3, 1.0] | <0.001  |
| 21. Difficult to perform sports activities | 0.0 [0.0, 1.0]  | 1.5 [1.0, 2.8] | <0.001  |
| 22. Restricted from meeting friends        | 0.0 [0.0, 1.0]  | 2.0 [1.0, 3.0] | <0.001  |
| 23. Restricted from joining social activities | 1.0 [0.0, 1.0]  | 3.0 [1.0, 4.0] | <0.001  |
| 24. Anxious about falls in house           | 0.0 [0.0, 0.8]  | 1.0 [0.0, 1.0] | 0.009   |
| 25. Anxious about being unable to walk in the future | 1.0 [0.0, 1.0]  | 1.0 [1.0, 1.0] | <0.001  |

LS: locomotive syndrome
GLFS-25: 25-question Geriatric Locomotive Function Scale
Data are presented as median [interquartile range]. Locomotive syndrome was defined as ≥16 points on the GLFS-25. P<0.05 was considered statistically significant.
Table 4 shows odds ratios (ORs) for LS at 1 year based on univariable and multivariable logistic regression analyses. The development of LS at 1 year was significantly associated with BMI (OR: 1.11 [95%CI: 1.00–1.22]), CDAI (OR: 1.08 [95%CI: 1.00–1.16]), and GLFS-25 (OR: 1.15 [95%CI: 1.03–1.27]) in multivariable logistic regression analyses. When linear regression was performed using the same variables as in Table 4, the change in the GLFS-25 at 1 year after baseline was only associated with GLFS-25 at baseline (regression coefficient: −0.36, 95%CI: −0.56 – −0.16). Significant associations between BMI, CDAI, and GLFS-25 at baseline and the development of LS were detected based on ROC curve analysis. The area under the ROC curve (AUC) was 0.633 (95%CI: 0.541–0.725) for BMI, and the best cut-off was 22.9 kg/m² (sensitivity, 50.0%; specificity, 69.5%). The AUC was 0.670 (95%CI: 0.577–0.762) for CDAI, and the best cut-off was 1.2 (sensitivity, 81.6%; specificity, 48.0%). The AUC was 0.718 (95%CI: 0.641–0.795)

Table 4  Baseline factors for development of LS at 1 year by logistic regression analysis

| Variables                        | Univariable OR | Multivariable OR |
|----------------------------------|----------------|------------------|
|                                  | OR (95% CI)    | p-value          | OR (95% CI)    | p-value |
| Age (years)                      | 0.99 (0.97–1.02) | 0.758            | —               | —       |
| Duration of disease (years)      | 0.97 (0.92–1.01) | 0.172            | —               | —       |
| Sex, female                      | 1.19 (0.55–2.58) | 0.657            | —               | —       |
| BMI (kg/m²)                      | 1.15 (1.05–1.26) | 0.003            | 1.11 (1.00–1.22) | 0.043   |
| Married                          | 0.55 (0.27–1.09) | 0.087            | 0.64 (0.29–1.39) | 0.260   |
| School education ≥ 13 years      | 1.15 (0.56–2.38) | 0.696            | —               | —       |
| Steinbrocker stage (3/4)         | 0.50 (0.22–1.13) | 0.095            | 0.44 (0.18–1.06) | 0.068   |
| Glucocorticoid use               | 1.40 (0.65–2.99) | 0.390            | —               | —       |
| Methotrexate use                 | 0.64 (0.32–1.30) | 0.214            | —               | —       |
| Other csDMARD use                | 1.25 (0.63–2.47) | 0.529            | —               | —       |
| bDMARD or tsDMARD use            | 1.39 (0.70–2.80) | 0.348            | —               | —       |
| Rheumatoid factor positive       | 1.20 (0.57–2.54) | 0.639            | —               | —       |
| CDAI                             | 1.08 (1.02–1.14) | 0.011            | 1.08 (1.00–1.16) | 0.046   |
| KCL                              | 1.16 (1.04–1.29) | 0.007            | 1.10 (0.97–1.25) | 0.137   |
| GLFS-25                          | 1.20 (1.10–1.31) | <0.001           | 1.15 (1.03–1.27) | 0.009   |

LS: locomotive syndrome
OR: odds ratio
CI: confidence interval
BMI: body mass index
DMARD: disease-modifying antirheumatic drugs
csDMARD: conventional synthetic DMARD
bDMARD: biological DMARD
tsDMARD: targeted synthetic DMARD
CDAI: Clinical Disease Activity Index
KCL: The Kihon Checklist
GLFS-25: 25-question Geriatric Locomotive Function Scale
Locomotive syndrome was defined as ≥16 points on the GLFS-25. Other csDMARDs include salazosulfapyridine, tacrolimus, bucillamine, and iguratimod. P<0.05 was considered statistically significant.
for GLFS-25, and the best cut-off was 9 points (sensitivity, 73.7%; specificity, 69.4%). Table 5 shows the ORs of baseline GLFS-25 categories and their changes for the development of LS at 1 year by logistic regression analyses. The development of LS at 1 year was significantly associated with the baseline “Body pain” category (OR: 1.29 [95%CI: 1.05–1.58]) and all changes in GLFS-25 categories except for the change in the “Usual care” category, with the change in the “GLFS-5” category having the highest OR (2.57 [95%CI: 1.75–3.77]).

Table 6 shows correlation coefficients (r) between changes in GLFS-25 categories in the LS group. The highest correlation coefficient was observed between the change in the “Social activities” category and that of the “GLFS-5” category (r=0.442).

Table 5 GLFS-25 categories for development of LS at 1 year by logistic regression analysis

| Variables                     | Multivariable OR | p-value |
|-------------------------------|------------------|---------|
|                               | OR (95% CI)      |         |
| **Baseline**                  |                  |         |
| Social activities             | 1.13 (0.96–1.33) | 0.148   |
| Body pain                     | 1.29 (1.05–1.58) | 0.016   |
| Cognitive                     | 1.37 (0.94–1.99) | 0.105   |
| GLFS-5                        | 1.17 (0.95–1.44) | 0.153   |
| Movement-related difficulty    | 1.38 (0.72–2.62) | 0.330   |
| Usual care                    | 1.10 (0.64–1.88) | 0.740   |
| **Change**                    |                  |         |
| ΔSocial activities            | 1.41 (1.16–1.73) | <0.001  |
| ΔBody pain                    | 1.68 (1.25–2.27) | <0.001  |
| ΔCognitive                    | 1.99 (1.15–3.45) | 0.014   |
| ΔGLFS-5                       | 2.57 (1.75–3.77) | <0.001  |
| ΔMovement-related difficulty   | 2.45 (1.15–5.21) | 0.020   |
| ΔUsual care                   | 1.31 (0.72–2.39) | 0.379   |

LS: locomotive syndrome
OR: odds ratio
CI: confidence interval
GLFS-25: 25-question Geriatric Locomotive Function Scale
Locomotive syndrome was defined as ≥16 points on the GLFS-25. Body pain includes question Nos. 1, 2, 3, and 4. Movement-related difficulty includes question Nos. 5, 6, and 7. Usual care includes question Nos. 8, 9, 10, 11, and 14. GLFS-5 includes question Nos. 12, 13, 15, 17, and 20. Social activities includes question Nos. 18, 21, 22, and 23. Cognitive includes question Nos. 24 and 25. Δ indicates change in score between baseline and 1 year later. OR for 1-score increase. P<0.05 was considered statistically significant.
DISCUSSION

The present study, to our knowledge, is the first to longitudinally investigate the development of LS in RA patients during the COVID-19 pandemic by using the GLFS-25. We previously reported that 15 of 58 RA patients (25.9%) developed LS, as defined by GLFS-25, in a 5-year longitudinal cohort study prior to the COVID-19 pandemic. In the present study, 38 of 286 RA patients (13.3%) developed LS within a one-year period during the COVID-19 pandemic, suggesting that LS of RA patients progressed compared to the natural course of the disease. The development of LS was significantly associated with CDAI and BMI at baseline (Table 4). With respect to GLFS-25 categories, while scores in the “Social activities” category of the non-LS group were increased at 1 year relative to baseline (Table 2), the LS group had higher scores in the “Body pain” and “Social activities” categories relative to other categories at baseline (Table 3), and had even higher scores in the “Social activities” and “GLFS-5” categories at 1 year (Fig. 1c and Table 3). Furthermore, the baseline “Body pain” category and the change in the “GLFS-5” category were significantly associated with the development of LS at 1 year (Table 5), and the change in the “Social activities” category was significantly associated with that of the “GLFS-5” category (Table 6). In other words, RA patients with LS, who felt body pain and refrained from going out at baseline, further refrained from going out and experienced a deterioration in physical function related to activities of daily living (eg, going up and down stairs, walking briskly, and carrying out load-bearing tasks and housework). Among the questions of the GLFS-25, GLFS-5 is set as a key domain, and is considered to be more affected in the early stages of LS. Naturally, scores of the “Social activities” category increased as a result of refraining from going out during the COVID-19 pandemic. This could have resulted in a higher GLFS-25 score without a concomitant deterioration of physical function. However, we found that, in addition to the “Social activities” category, scores of the “GLFS-5” category also increased in the LS group. This highlights the importance of asking RA patients questions from

| Variables | ΔSocial activities | ΔBody pain | ΔCognitive | ΔGLFS-5 | ΔMRD |
|-----------|-------------------|------------|------------|---------|------|
| r         | p                 | r          | p          | r       | p    |
| ΔBody pain| -0.083            | 0.620      | —          | —       | —    |
| ΔCognitive| 0.130             | 0.438      | 0.042      | 0.802   | —    |
| ΔGLFS-5   | 0.442             | 0.006      | 0.096      | 0.565   | 0.236|
| ΔMRD      | -0.112            | 0.502      | 0.248      | 0.134   | 0.197|
| ΔUsual care| 0.062             | 0.713      | 0.396      | 0.014   | 0.186|

LS: locomotive syndrome

r: correlation coefficient
p: p-value

GLFS-25: 25-question Geriatric Locomotive Function Scale

MRD: Movement-related difficulty

Locomotive syndrome was defined as ≥16 points on the GLFS-25. Body pain includes question Nos. 1, 2, 3, and 4. MRD includes question Nos. 5, 6, and 7. Usual care includes question Nos. 8, 9, 10, 11, and 14. GLFS-5 includes question Nos. 12, 13, 15, 17, and 20. Social activities includes question Nos. 18, 21, 22, and 23. Cognitive includes question Nos. 24 and 25. Δ indicates change in score between baseline and 1 year later. P<0.05 was considered statistically significant.
the GLFS-5 to easily evaluate whether their physical function has deteriorated or not.

There was some variation regarding subjects who had low GLFS-25 scores and those who did not, despite their similar circumstances of refraining from going out during the COVID-19 pandemic. This variation may have been influenced by RA patient characteristics and associated behavioral patterns. We found the mean score (SD) of CDAI at baseline in the LS group to be 5.7 (5.1), which was significantly higher than that in the non-LS group (Table 1). In addition, CDAI at baseline was a significant factor in the development of LS (Table 4). Among GLFS-25 categories at baseline, the proportion of subjects experiencing “Body pain” in the LS group was relatively high (Fig. 1c and Table 3), and the cut-off point for CDAI at baseline was 1.2, with high sensitivity. In other words, if CDAI is ≤1.2 (corresponding to CDAI remission, ie, CDAI ≤2.8), the possibility of developing LS is low. This suggest that tight painless control of RA disease activity for deeper remission is important for preventing the development of LS during the COVID-19 pandemic. On the other hand, if RA patients suffered from pain or had low to higher disease activity, rheumatologists should consider proper interventions against LS at an appropriate stage in addition to RA treatment, given that RA patients are susceptible to developing LS.

Interestingly, BMI at baseline was significantly associated with the development of LS (Table 4). It is worth noting that the higher the BMI, the worse the GLFS-25 score was and the more likely it is to develop LS. Low BMI (<18.5 kg/m²) is one of the 25 items in the KCL, which is used to diagnose frailty, and a symptom of sarcopenia. Since LS is a condition caused by disorders of the musculoskeletal system, low BMI is considered a risk factor for LS. On the other hand, both high BMI, as well as low BMI, are reportedly associated with frailty.

High BMI is also associated with LS. Notably, the findings may derive from the fact that high BMI is associated with knee osteoarthritis, a causative disease of LS. Moreover, high BMI (obesity) is a risk factor for severity of COVID-19. This is because obesity affects the immune system, and the secretion of cytokines and adipokines from adipose tissue leads to a pro-inflammatory state, inadequate antibody response, and a cytokine storm. Refraining from going out can lead to a lack of exercise, resulting in a condition referred to as “COVID-19 obesity”. Therefore, attention should be paid to patients with a BMI >22 kg/m², the LS cut-off point determined in the present study. “22 kg/m²” just corresponds to ideal BMI with the lowest morbidity. Certainly, while it is important to avoid going out during the COVID-19 pandemic to prevent the spread of the disease, it is just as important to increase physical activity through exercise and to maintain and improve physical function. Adequate exercise can reduce pain in RA patients. Moreover, we found that scores of the “Cognitive” category were significantly increased in the LS group. Since exercise can also relieve anxiety, being physically active is all the more important during the COVID-19 pandemic.

This study has several limitations. First, LS was defined using the GLFS-25, and tests for locomotive function, such as the stand-up test and the two-step test, were not performed. Thus, it is possible that subjects identified as having LS based on the GLFS-25 may differ from those identified using the stand-up test or two-step test. This could have led to an overestimation of LS in the present study, given the possibility that “Social activities” or “Cognitive” category scores may have increased during the COVID-19 pandemic. However, since the study was initiated during the COVID-19 pandemic and our patients did not have LS (as determined by the GLFS-25) at baseline, extracted factors other than GLFS-25 which are related to development of LS (CDAI and BMI at baseline), as well as the significant changes observed in GLFS-25 (including on a category-by-category basis), are considered to be valid. Nonetheless, future studies which use the stand-up test and two-step test will be necessary to validate our present results. Second, we did not obtain information regarding the history of surgery, comorbidities, complications, or detailed treatments from subjects. However, we did obtain information regarding the use of
MTX, other csDMARDs, bDMARDs/tsDMARDs, and GC, as well as disease activity, which are important factors for better understanding the RA patient population. Third, the follow-up period was from June and August 2020 (at baseline) to between June and August 2021 (at 1 year), which was not exactly 1 year. Finally, psychosocial factors such as depression, anxiety, and social support, which could impact the decision to refrain from going out, social activities, and LS, were not evaluated in detail. However, the KCL contains questions about psychosocial factors, which were not identified as factors associated with the development of LS in the multivariable logistic regression analyses, although they were significant in the univariable analyses (Tables 1 and 4). Since the above-mentioned factors can affect physical function and RA disease activity, future studies that take these into account are warranted.

In conclusion, we investigated longitudinally the development of LS in RA patients during the COVID-19 pandemic, and identified CDAI and BMI at baseline as being associated with the development of LS. With respect to GLFS-25 categories, GLFS-5 was found to be important for evaluating the physical function of RA patients. These findings suggest that the tight painless control of RA disease activity for deeper remission, as well as exercise, are important for maintaining physical function and preventing LS during the COVID-19 pandemic.

ACKNOWLEDGMENTS

We thank Ms Sachiko Kato, Ms Emi Yokota, Ms Ritsuko Otake, and Ms Takako Sashikata for their assistance with information collection.

CONFLICT OF INTEREST

None to report.

FUNDING

This research was supported by AMED under Grant Number JP21ek0410086.

REFERENCES

1. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med.* 2020;382(13):1199–1207. doi:10.1056/NEJMoa2001316.
2. Sakurai A, Sasaki T, Kato S, et al. Natural History of Asymptomatic SARS-CoV-2 Infection. *N Engl J Med.* 2020;383(9):885–886. doi:10.1056/NEJMc2013020.
3. Atzrodt CL, Maknojia I, McCarthy RDP, et al. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. *FEBS J.* 2020;287(17):3633–3650. doi:10.1111/febs.15375.
4. Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID-19 Pandemic: Version 1. *Arthritis Rheumatol.* 2020;72(8):1241–1251. doi:10.1002/art.41301.
5. Sanchez-Piedra C, Diaz-Torne C, Manero J, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. *Ann Rheum Dis.* 2020;79(7):988–990. doi:10.1136/annrheumdis-2020-217948.
6. Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. *Ann Rheum Dis.* 2021;80(9):1137–1146. doi:10.1136/annrheumdis-2021-220418.
7. Watanabe T, Yabu T. Japan’s voluntary lockdown. *PLoS One.* 2021;16(6):e0252468. doi:10.1371/journal.
RA locomotive syndrome and COVID-19

1. Tison GH, Avram R, Kuhar P, et al. Worldwide Effect of COVID-19 on Physical Activity: A Descriptive Study. Ann Intern Med. 2020;173(9):767–770. doi:10.7326/M20-2665.

2. Nakamura K. A “super-aged” society and the “locomotive syndrome”. J Orthop Sci. 2008;13(1):1–2. doi:10.1007/s00776-007-1202-6.

3. Nakamura K, Ogata T. Locomotive Syndrome: Definition and Management. Clin Rev Bone Miner Metab. 2016;14(2):56–67. doi:10.1007/s12188-016-9208-2.

4. Sobue Y, Suzuki M, Ohashi Y, et al. Relationship between locomotive syndrome and frailty in rheumatoid arthritis patients by locomotive syndrome stage. Mod Rheumatol. 2021; rob024. doi:10.1093/mr/rob024.

5. Imagama S, Hasegawa Y, Ando K, et al. Staged decrease of physical ability on the locomotive syndrome risk test is related to neuropathic pain, nociceptive pain, shoulder complaints, and quality of life in middle-aged and elderly people - The utility of the locomotive syndrome risk test. Mod Rheumatol. 2017;27(6):1051–1056. doi:10.1080/14397595.2017.1285856.

6. Imagama S, Ando K, Kobayashi K, et al. Differences of locomotive syndrome and frailty in community-dwelling middle-aged and elderly people: Pain, osteoarthritis, spinal alignment, body balance, and quality of life. Mod Rheumatol. 2020;30(5):921–929. doi:10.1080/14397595.2019.1665616.

7. Kojima M, Nakayama T, Tsutani K, et al. Epidemiological characteristics of rheumatoid arthritis in Japan: Prevalence estimates using a nationwide population-based questionnaire survey. Mod Rheumatol. 2020;30(6):941–947. doi:10.1080/14397595.2019.1682776.

8. Kato E, Sawada T, Tahara K, et al. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis. 2017;20(7):839–845. doi:10.1111/i1756-185X.12998.

9. Imagama S, Kojima T, Funahashi K, et al. Relationship between disease activity of rheumatoid arthritis and development of locomotive syndrome: A five-year longitudinal cohort study. Mod Rheumatol. 2021;31(1):101–107. doi:10.1080/14397595.2020.1744828.

10. Seichi A, Kimura A, Konno S, Yabuki S. Epidemiologic survey of locomotive syndrome in Japan. J Orthop Sci. 2016;21(2):222–225. doi:10.1016/j.jos.2015.12.012.

11. Sobue Y, Kojima T, Funahashi K, et al. Relationship between rheumatoid arthritis and locomotive syndrome: validation of the 25-question Geriatric Locomotive Function Scale in patients with rheumatoid arthritis. Nagoya J Med Sci. 2019;81(3):453–462. doi:10.18999/nagjms.81.3.453.

12. Izawa N, Hirose J, Fujii T, et al. The utility of 25-question Geriatric Locomotive Function Scale for evaluating functional ability and disease activity in Japanese rheumatoid arthritis patients: A cross-sectional study using NinJa database. Mod Rheumatol. 2019;29(2):328–334. doi:10.1080/14397595.2018.1457422.

13. Seichi A, Hoshino Y, Doi T, Akai M, Tobimatsu Y, Iwaya T. Development of a screening tool for risk of locomotive syndrome in the elderly: the 25-question Geriatric Locomotive Function Scale. J Orthop Sci. 2012;17(2):163–172. doi:10.1007/s00776-011-0193-5.

14. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404–413. doi:10.1136/ard.2011.149765.

15. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi:10.1002/art.27584.

16. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659–662. doi:10.1001/jama.1949.02900430001001.

17. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26(11):1346–1353. doi:10.1002/art.1780261107.

18. Satake S, Senda K, Hong YJ, et al. Validity of the Kihon Checklist for assessing frailty status. Geriatr Gerontol Int. 2016;16(6):709–715. doi:10.1111/ggi.12543.

19. Arai H, Satake S. English translation of the Kihon Checklist. Geriatr Gerontol Int. 2015;15(4):518–519. doi:10.1111/ggi.12397.

20. The Japanese Orthopaedic Association. Locomo-pamphlet 2020 [in Japanese]. https://locomo-joa.jp/assets/pdf/index_japanese.pdf. Published September 2020. Accessed November 25, 2021.

21. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi:10.1038/bmt.2012.244.

22. Yamada M, Kimura Y, Ishiyama D, et al. Letter to the Editor: Recovery of Physical Activity among Older Japanese Adults since the First Wave of the COVID-19 Pandemic. J Nutr Health Aging. 2020;24(9):1036–1037. doi:10.1007/s12603-020-1466-5.
30 Maugeri G, Castrogiovanni P, Battaglia G, et al. The impact of physical activity on psychological health during Covid-19 pandemic in Italy. *Heliyon*. 2020;6(6):e04315. doi:10.1016/j.heliyon.2020.e04315.
31 Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J Am Med Dir Assoc*. 2020;21(3):300–307.e2. doi:10.1016/j.jamda.2019.12.012.

32 Ozeki S, Takeuchi K, Yasuoka M, et al. Comparison of frailty associated factors between older adult patients with rheumatoid arthritis and community dwellers. *Arch Gerontol Geriatr*. 2021;96:104455. doi:10.1016/j.archger.2021.104455.

33 Ohtsuki M, Nishimura A, Kato T, et al. Relationships between body mass index, lifestyle habits, and locomotive syndrome in young- and middle-aged adults: A cross-sectional survey of workers in Japan. *J Occup Health*. 2019;61(4):311–319. doi:10.1002/1348-9585.12053.

34 Liu Y, Zhang H, Liang N, et al. Prevalence and associated factors of knee osteoarthritis in a rural Chinese adult population: an epidemiological survey. *BMC Public Health*. 2016;16:94. doi:10.1186/s12889-016-2782-x.

35 Terada M, Ohitsu H, Saito S, et al. Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. *BMJ Open*. 2021;11(6):e047007. doi:10.1136/bmjopen-2020-047007.

36 Aghili SMM, Ebrahimpur M, Arjmand B, et al. Obesity in COVID-19 era, implications for mechanisms, comorbidities, and prognosis: a review and meta-analysis. *Int J Obes (Lond)*. 2021;45(5):998–1016. doi:10.1038/s41366-021-00776-8.

37 Tokunaga K, Matsuzawa Y, Kotani K, et al. Ideal body weight estimated from the body mass index with the lowest morbidity. *Int J Obes*. 1991;15(1):1–5.

38 Sobue Y, Kojima T, Ito H, et al. Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? - A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis. *Mod Rheumatol*. 2021;1–14. doi:10.1080/14397595.2021.1886653.

39 Stonerock GL, Hoffman BM, Smith PJ, Blumenthal JA. Exercise as Treatment for Anxiety: Systematic Review and Analysis. *Ann Behav Med*. 2015;49(4):542–556. doi:10.1007/s12160-014-9685-9.

40 Brady SM, Fenton SAM, Metsios GS, et al. Different types of physical activity are positively associated with indicators of mental health and psychological wellbeing in rheumatoid arthritis during COVID-19. *Rheumatol Int*. 2021;41(2):335–344. doi:10.1007/s00296-020-04751-w.